Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04090242
Other study ID # DBC-19BRGHT02
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 6, 2019
Est. completion date June 12, 2020

Study information

Verified date June 2021
Source Becton, Dickinson and Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, open-label, parallel-group, randomized controlled study in subjects with type 2 diabetes using multiple daily injection (MDI) insulin therapy. Subjects will be randomized to either receive the DC App and BD Nano 2nd Gen pen needles (intervention) or continue their standard of care using their current pen needle and diabetes management (control). The study will consist of four visits and two scheduled phone calls across a total of 10 weeks.


Description:

At Visit 1 (Day -14) site staff will screen and enroll qualified subjects, provide a BGM (Accu-Chek Guide) and attach a blinded flash glucose sensor (Libre Freestyle) to the back of the arm. Subjects will complete any applicable baseline Patient Reported Outcomes (PRO) questionnaires and be sent home with no changes to their current therapy. While at home Subjects will be asked to test blood glucoses using the provided BGM and continue their usual insulin dosing before returning to clinic for Visit 2. Visit 2 will consist of randomization (Interventional Group or Control Group). The control group will be continued on their current pen needle and receive standard visit education as needed. The intervention group will be trained on the use of the DC App and be switched to BD Nano 2nd Gen pen needle. During weeks 3 through 8, subjects in both groups will continue their usual insulin routine, with the control group adhering to their usual practice of managing their diabetes and the intervention group utilizing the DC app for relevant educational content and tips plus using the BD Nano 2nd Gen for all insulin injections. During Visit 3 subjects will get a 2nd fGM sensor placed and be instructed to continue their insulin routine for the final 2 weeks. Visit 4 is the last visit where subjects will have their fGM removed, return the BGM, complete applicable PRO surveys, an injection technique questionnaire and be discharged.


Recruitment information / eligibility

Status Terminated
Enrollment 58
Est. completion date June 12, 2020
Est. primary completion date June 12, 2020
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: 1. 22 years of age minimum 2. Adult subjects with type 2 diabetes mellitus on Multiple daily injections (MDI) and giving themselves at least 2 injections of insulin / day using a pen injector. This may include at minimum i. giving 1 basal injection and at least 1 meal time injection or ii. giving at least 2 daily injections of mixed insulins or iii. giving 2 meal time injections iv. two injections of basal insulin per day will not be considered MDI for this study v. additional OAD/non-insulin injectable therapy is acceptable 3. Must currently be on MDI insulin therapy for at least 6 months prior to enrollment and, in the opinion of the investigator, would benefit from dose optimization. 4. Willing to use the BD provided BGM for the study duration. 5. Hemoglobin A1C of 8.0 - 11% at screening (tested at enrollment unless Subject has a documented HbA1c value on file at the site that was drawn within 3 months of enrollment date). 6. In stable health status with no acute or significant illness, based on the opinion of the investigator. 7. Able to read, write and follow instructions in English (translations will not be provided). 8. Currently using a smartphone and able to understand the use of mobile apps. 9. Able and willing to provide informed consent. 10. Able and willing to follow study procedures. Exclusion Criteria: - Subjects with any one of the following characteristics will be excluded from participation: 1. Pregnant or breast feeding- self reported. 2. Subject on basal-only 3. Uncontrolled comorbidities or acute illness 4. Currently using Nano 2nd Gen pen needles 5. Use of a smartphone with iOS 10.0 or lower or with Android OS 5.0 "Lollipop" or lower 6. Use of CGM or fGM less than 6 months and not proficient in its use, however this may be left up to the investigators discretion. i. Subjects may continue to wear their own CGM/fGM during their participation in this study if they adhere to the testing of blood glucose using the site provided BGM. 7. Subjects not on stable doses of concomitant non-insulin diabetes medications. Stable is defined as not requiring new non-insulin diabetes medications or any changes in dosing of current non-insulin diabetes medication during study participation (10 weeks) unless warranted by investigator for the safety of the subject. 8. Actively using one of the following diabetes management apps deemed similar and not willing to stop using it during participation on the study (exclusionary apps; Onedrop, Welldoc (Bluestar), Dario, Sugar Sense Glucose, Buddy, mySugr, Omada, Livongo, Accu-Check Connect, SugarIQ). 9. Known sensitivity to adhesives. 10. Currently using the DC app. 11. Employed by, or currently serving as a contractor or consultant to BD or study site 12. Any other condition the investigator deems to pose a risk to the Subject in the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle
Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.

Locations

Country Name City State
United States Texas Diabetes and Endocrinology Austin Texas
United States East West Medical Research Institute Honolulu Hawaii
United States Mills Pennisula Medical Center-Diabetes Research Institute San Mateo California
United States Metabolic Research Institute West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Becton, Dickinson and Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of Hypoglycemic Events (<70mg/dL and <54mg/dL) at Baseline and Study End Frequency of hypoglycemia: The number of hypoglycemic events (<70mg/dL and <54mg/dL) as measured by blood glucose monitor (BGM) will be collected to determine frequency of hypoglycemia in each group. Baseline (Day -14) to Study End (Day 56)
Other Number of Hours of Patient Engagement With App Patient Engagement: Engagement with The DC App will be measured by app collected usage analytics and main assessment was time spent within app. Baseline (Day 1) to Study End (Day 56)
Primary Change in Attitude Toward Diabetes - Diabetes Empowerment Scale (DES) From Baseline to End of Study A standardized questionnaire including 8 questions with response categories of 'strongly disagree', 'somewhat disagree', 'neutral', 'somewhat agree', and 'strongly agree'. An overall score for the DES is calculated by summing all of the item scores and dividing by 8 for a possible score range of 1-5 where a higher score indicates a higher level of empowerment. Baseline (Day -14) and Study End (Day 56)
Secondary Change in 24 Hour Average Blood Glucose From Baseline to End of Study Freestyle Libre Pro blinded flash glucose monitoring will be used to assess change in average 24 hour blood glucose between groups Subjects will wear Libre sensors on the backs of their arm for the 2 weeks at the beginning of the study and 2 weeks at the end of the study. Baseline (Day -14 through Day -1) and Study End (Day 42 through Day 56)
Secondary Blood Glucose Values in Range of <54 mg/dL at Baseline Compared to End of Study Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end. For example, Time below 54 mg/dl is calculated in the following manner: Number of all glucose data points below 54 mg/dl / total number of glucose data points X 100. Since data points are all 5 minutes apart, this calculation provides the percentage of time in that range. Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Secondary Blood Glucose Values in Range of <70 mg/dL at Baseline Compared to End of Study Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end. Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Secondary Blood Glucose Values Between 70 mg/dL and 180 mg/dL at Baseline Compared to End of Study Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end. Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Secondary Blood Glucose Values in Range of >180mg/dL at Baseline Compared to End of Study Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end. Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Secondary Blood Glucose Values in Range of >250 mg/dL at Baseline Compared to End of Study Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end. Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Secondary Change in Mean Amplitude of Glycemic Excursion (MAGE) Between Baseline and End of Study Flash glucose monitoring data were used to measure glycemic variability changes at baseline and study end between groups. Measuring glycemic variability helps determine how much glucose levels change over the course of a day or between days. Baseline (Day -14 through Day -1) and Study End (Day 42 through Day 56)
Secondary Change in Diabetes Distress Screening Scale - 17 (DDS17) Scores From Baseline to End of Study A standardized questionnaire including 17, 6-point Likert Scale questions where 1 indicates "Not a problem", 2 indicates "A slight problem", 3 means "A moderate problem", 4 indicates a "Somewhat serious problem", 5 indicates "A serious problem", and 6 means "A very serious problem". Using this scale, a Total Score, Emotional Burden Score, Physician Score, Regimen Distress Score, and Interpersonal Score were calculated. Baseline (Day -14) to Study End (Day 56)
Secondary Insulin Delivery System Rating Questionnaire (IDSRQ) Scores at Baseline and End of Study A standardized questionnaire including several questions with ordinal response scales from 1 to 4 and 1 to 5. The IDSRQ has seven sub-scales (satisfaction, interference of treatment with daily activities, diabetes-related worries, clinical efficacy, psychological well-being, social burden, and treatment preference). Each sub-scale is calculated as a mean of their corresponding items with scores ranging from 0-100. Higher scores represent higher levels of satisfaction, perceived clinical efficacy, and psychological well-being, interference with daily activities, diabetes-related worries, and social burden. Baseline (Day -14) and Study End (Day 56)
Secondary Adherence to Refills and Medications Scale for Diabetes (ARMS-D) Questionnaire Scores at Baseline and Study End A standardized questionnaire including 11 multiple choice questions. The ARMS-D yields a total score plus two sub-scale scores (refill sub-scale and medication taking sub-scale. Items 1-10 are scored as follows: 1= none of the time, 2 = some of the time, 3 = most of the time, and 4 = all of the time. Item 11 is reversed scored. The ARMS-D total is a sum of all items for a possible score ranging from 11-44. The ARMS-D refill sub-scale is a sum of 4 items for a possible score ranging from 4-16. The ARMS-D medication taking sub-scale is a sum of 7 items for a possible score ranging from 7-28. Lower scores indicate better adherence. Baseline (Day -14) to Study End (Day 56)
Secondary Patient Satisfaction at Study End A questionnaire including 16, 5-point Likert Scale questions where 1 indicates strongly disagree and 5 indicates strongly agree. This questionnaire yields a total satisfaction score plus three sub-scale scores (mobile app satisfaction, pen needle satisfaction, and injection management system satisfaction). The total score ranges from 16-80. The mobile app and pen needle satisfaction sub-scale score range from 6-30 and is a sum of all items in the associated sub-scale. The management system sub-scale score ranges from 4-20 and is a sum of all items in the sub-scale. Higher scores indicate higher satisfaction. Administered to participants in the Intervention group only at end of study (Day 56)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4